

## REIMBURSEMENT KIT



Contact marketaccess@hemady.com for more information on Hemady®



## Product Information



NDC	Package Size	
82111-0955-01	24 tablets	
82111-0955-02	100 tablets	

### ICD-10 Codes for Multiple Myeloma (MM)


**C90.00** – MM not having achieved remission

**C90.01** – MM in remission

**C90.02** – MM in relapse

### Hemady® Team Contact Information

For more information, please contact your representative or email <a href="marketaccess@hemady.com">marketaccess@hemady.com</a>







# Hemady<sup>®</sup> is Available Through the Following Specialty Pharmacy:

#### **Walgreens Specialty Pharmacy**

Phone: 855-244-2555 Fax: 877-235-9807

**Disclaimer:** Specialty pharmacy supply and availability of Hemady® are subject to change. Please check with the specialty pharmacy to confirm availability of Hemady®.

#### **Enrollment Form**

A fillable form can be found by scanning the QR code below



### Hemady<sup>®</sup> is Available Through the Following <u>Group Purchasing Organizations</u>:

### Cardinal Health™ VitalSource™ GPO

100-Count Bottle: **5893409** 

24-Count Bottle: **5893391** 

# Cencora Oncology Supply

100-Count Bottle: **10284671** 

24-Count Bottle: 10284636

# Cencora ASD Healthcare

100-Count Bottle: 10284663

24-Count Bottle: 10284623

### McKesson Specialty

100-Count Bottle: 5016794

24-Count Bottle: 5016793



#### Walgreens Specialty Pharmacy is a partner for Hemady®

Phone #: 855-244-2555 | Fax #: 877-235-9807

Note: This form is intended for prescriber use only, if faxed, the fax must come from HCP office or hospital (may not be faxed by patient).

# Patient Enrollment & Prescription Form

Patient Information			
Name:	Date of Birth:		Gender: Male Female
Address:			City:
State: Zip:	Phone #:	Email:	
Alternative Contact:		Alternative Contact Pho	one #:
Insurance Information	1		
Rx Insurance Name:		Rx Insurance BIN #:	
nsurance Phone #:		Rx Insurance PCN #:	
1 Please provide front	& back copies of patient	s Rx insurance card(s), i	include any secondary coverage
Clinical Information		C90.	CD-10 Codes for Multiple Myeloma (MM) 00 – MM not having achieved remission
Primary ICD-10 Code:	Secondary ICD-10		01 – MM in remission 02 – MM in relapse
Allergies:			☐ Ib ☐ kg
Other Medications:			
			armacy along with referral form
Prescriber Information	1		
Prescriber Name:	NPI#:		License #:
Drugotico Addresos			City:
State: Zip:	Office Phone #:	Offic	
Office Contact Name:			
Prescription Informati	on	NDC Codes: 821	11-0955-01; 82111-0955-02
Hemady® (dexamethason	e) tablets, 20 mg		
- Sig:		Quantity:	Refills:
Prescriber Signature:		Prescriber Signature:	
Date: (Dispe	nse as written) © Edenbridge Pharmaceutio		(Substitution permissible)



# Prior Authorization Support

## Common Prior Authorization (PA) Submission Requirements

Diagnosis of MM (ICD-10)

Age ≥18

Prescribed by a hematology/oncology specialist

Verification of use in combination with other anti-myeloma therapies

Previous use of generic dexamethasone

### Sample Letter of Medical Necessity

Edenbridge offers a template

Letter of Medical Necessity as a resource healthcare providers can use for prescribing Hemady®



A customizable copy of this Letter can be found by scanning the QR code below



#### HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use HEMADY® safely and effectively. See full prescribing information for HEMADY. HEMADY (dexamethasone tablets), for oral use Initial U.S. Approval: 1958 ----RECENT MAJOR CHANGES-----Warnings and Precautions, Immunosuppression and Increased Risk of 6/2024 Infection (5.2) Warnings and Precautions, Kaposi's Sarcoma (5.11) 6/2024 --- INDICATIONS AND USAGE --HEMADY is a corticosteroid indicated in combination with other antimyeloma products for the treatment of adults with multiple myeloma. (1) -DOSAGE AND ADMINISTRATION --Recommended Dosage: 20 mg or 40 mg orally once daily, on specific days depending on the protocol regimen. (2) --- DOSAGE FORMS AND STRENGTHS ----Tablets: 20 mg (3) --- CONTRAINDICATIONS ---

- Patients with hypersensitivity to dexamethasone (4)
- Patients with systemic fungal infections (4)

#### -- WARNINGS AND PRECAUTIONS --

- Alterations in Endocrine Function: Hypothalamic-pituitary adrenal (HPA) axis suppression, Cushing's syndrome, and hyperglycemia can occur. Monitor patients for these conditions with chronic use. (5.1)
- Immunosuppression and Increased Risk of Infection: Increased risk of new, exacerbation, dissemination, or reactivation of latent infections. (5.2)
- Alteration in Cardiovascular/Renal Function: Monitor for elevated blood pressure and sodium, and for decreased potassium levels. (5.3)
- Venous and Arterial Thromboembolism: Risk increased; consider anticoagulant prophylaxis and monitor for evidence of thromboembolism.
- Vaccination: Avoid the administration of live or live attenuated vaccines in patients receiving immunosuppressive doses of corticosteroids. (5.5)
- Ophthalmic Effects: May include cataracts, infections, and glaucoma. (5.6)

- Gastrointestinal Perforation: Avoid use in active or latent peptic ulcers, diverticulitis, fresh intestinal anastomoses, and nonspecific ulcerative colitis, since they may increase the risk of a perforation. (5.7)
- Osteoporosis: Increased risk; monitor for changes in bone density with chronic use. (5.8)
- Behavioral and Mood Disturbances: May include euphoria, insomnia, mood swings, personality changes, severe depression, and psychosis. Monitor for signs and symptoms and manage promptly. (5.10)
- Kaposi's Sarcoma: Kaposi's sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. (5.11)
- Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus. (5.13, 8.1)

A DATE DE LOTTONO	
 ADVERSE REACTIONS	

The most common adverse reactions are cardiovascular, dermatologic, endocrine, fluid and electrolyte disturbances, gastrointestinal, metabolic, musculoskeletal, neurological/psychiatric, ophthalmic, abnormal fat deposits, decreased resistance to infection, hiccups, increased or decreased motility and number of spermatozoa, malaise, moon face, and weight gain. (6)

To report SUSPECTED ADVERSE REACTIONS, contact Edenbridge Pharmaceuticals, LLC, at 877-381-3336 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

#### - DRUG INTERACTIONS --

- Avoid concomitant use of strong CYP3A4 inhibitors or inducers. (7.1)
- Concomitant therapies such as erythropoietin stimulating agents or estrogen containing therapies may have an increased risk of thromboembolism. (7.2)

--- USE IN SPECIFIC POPULATIONS --Lactation: Advise not to breastfeed. (8.2)

See 17 for PATIENT COUNSELING INFORMATION

Revised: 6/2024

Please visit www.hemady.com to review the Full Prescribing Information for Hemady®

